Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai reports positive results from Phase II breast cancer trial
Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had
Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had
In this interim analysis, 25 of 46 enrolled patients had sufficient data available for evaluation. The median follow up of the patients was six months (range two to
The Opus study is a randomized first-line Phase II study of 337 patients comparing Erbitux plus Folfox to Folfox alone in epidermal growth factor receptor (EGFR)-expressing colorectal cancer
Under the terms of the agreement, Dyax has been granted a non-exclusive research and development license for use of Novozymes’ technology to develop albumin fusions of Kunitz domain
Early results on the first three patients from this investigator-initiated study showed the increase in breast volume was maintained at three months and that the tissue remained soft
Top-line data from this Phase II safety and efficacy study of intestinal trefoil factor (rhITF) administered to colorectal cancer patients at high risk of developing oral mucositis (OM)
Overall, custirsen was well-tolerated in combination with either docetaxel or mitoxantrone administered as second-line chemotherapy in patients with hormone refractory prostate cancer. Custirsen was associated with durable pain
The Phase IIa study met its primary endpoint by showing a statistically significant reduction in mean 24-hour systolic ambulatory blood pressure over placebo. The study also showed statistically
The Ahead II study found that the milk-based product produced a mean drop in daytime, ambulatory systolic blood pressure of 3.6mmHg for the active group after six weeks
In addition, in post hoc analyses, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine (p